UBS analyst Ashwani Verma increased the price target for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to $30 from the previous $28 while keeping a Buy rating on the shares. Verma highlighted Teva as ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 15.45% ...

Oklo (OKLO) is a clean energy producer that aims to use advanced fission power plants to generate clean and affordable energy ...

Revenue decreased by 1.87% YoY & profit increased by 19.63% YoY, profit at ₹3805.94 crore and revenue at ₹127550.57 crore.